Skip to main content

ORIGINAL RESEARCH article

Front. Nutr.
Sec. Nutrition and Metabolism
Volume 11 - 2024 | doi: 10.3389/fnut.2024.1472104
This article is part of the Research Topic Nutrition and Metabolism in Cancer: Role in Prevention and Prognosis View all 23 articles

Prognostic Value of the Triglyceride-Glucose Index in Nonmuscle-invasive Bladder Cancer: A Retrospective Study

Provisionally accepted
Yan Zhang Yan Zhang 1Xianfeng Shao Xianfeng Shao 1Li Ding Li Ding 2Wentao Xia Wentao Xia 1Kun Wang Kun Wang 1*Shan Jiang Shan Jiang 1*Jiahao Wang Jiahao Wang 1*Junqi Wang Junqi Wang 1*
  • 1 Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
  • 2 Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, Shanghai Municipality, China

The final, formatted version of the article will be published soon.

    Background: Bladder carcinoma is a type of urological tumour with high risks of recurrence and progression. The triglyceride-glucose (TyG) index has demonstrated significant promise as a prognostic marker for metabolic health in different types of cancer. Further research is needed to explore the relationships among nonmuscleinvasive bladder cancer (NMIBC), the TyG index, and its prognostic importance.Purpose of this preliminary research is to assess the predictive significance of the TyG index for recurrence and progression risk in NMIBC patients.Methods: Data from patients admitted between October 2018 and July 2021 were reviewed, and there are 198 patients in total were included. The experimental data were supplied by medical records. In addition, patient prognoses were followed up via telephone. Furthermore, patients were separated into 2 groups: the high and low TyG groups, using X-tile software. Apart from recurrence-free survival (RFS), progressionfree survival (PFS) was the main outcome. According to the TyG index, nomograms were also established.The cohort consisted of 93 patients in the high TyG group and 105 patients in the low TyG group. The TyG index was a key prognostic factor for postoperative RFS (HR = 2.726, 95% CI = 1.474 -5.041, P =0.001) and PFS (HR = 2.846, 95% CI = 1.359-5.957, P =0.006) among patients with NMIBC. The log-rank test revealed a notable disparity between the low and high TyG groups regarding RFS (P =0.0025) and PFS (P =0.0110). Moreover, it was strongly connected to well-known NMIBC risk factors. Because the TyG index exhibited good predictive value, the nomogram models 2 were formulated.The TyG index serves as an isolated predictor of both RFS and PFS among patients with NMIBC, revealing new insights into disease treatment mechanisms. Indeed, the TyG index serves as a credible indicator of risk classification while facilitating early intervention among patients with NMIBC.

    Keywords: Bladder cancer, NMIBC, prognosis, TyG index, tumour recurrence, Insulin Resistance, nomogram

    Received: 28 Jul 2024; Accepted: 03 Dec 2024.

    Copyright: © 2024 Zhang, Shao, Ding, Xia, Wang, Jiang, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Kun Wang, Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
    Shan Jiang, Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
    Jiahao Wang, Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
    Junqi Wang, Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.